Pharmaceutical Technology

FEBRUARY 14, 2023

Innovation S-curve for Internet of Things in the pharmaceutical industry Nanoparticles for drug delivery is a key innovation A nanoparticle is a small particle ranging in size from 1 to 100 nanometres. Nanoparticles are used as novel drug delivery systems to deliver drugs to specific tissues and to provide controlled release therapy.

Drug Delivery 147

Drug Delivery Drugs Drug Delivery Systems FDA Approval 147

Drug Discovery World

AUGUST 9, 2023

The new acquisition gives Biogen rights to Reata’s portfolio of products for neurological diseases, including the FDA-approved Skyclarys (omaveloxolone), the only approved treatment for Friedreich’s ataxia (FA) in the United States.

Drugs 52

Drugs Drug Delivery Systems Drug Delivery Life Science 52

Delveinsight

NOVEMBER 26, 2020

However, for such a burdensome and highly prevalent sight-threatening eye disorder, the Retinal vein occlusion treatment market has no curative option to offer. Retinal vein occlusion drug market. The US FDA approved Lucentis in June 2010 for the treatment of macular edema following RVO.

FDA Approval 63

FDA Approval Marketing Drug Delivery Systems Drugs 63

XTalks

OCTOBER 27, 2021

Genentech’s ocular implant drug delivery system for treatment of macular degeneration has received approval from the US Food and Drug Administration (FDA). Susvimo delivers ranibizumab via a port delivery system into a surgically placed implant in the eye, allowing for continuous delivery of the drug.

Drug Delivery Systems 104

Drug Delivery Systems Drug Delivery FDA Approval Drugs 104

FDA Law Blog

SEPTEMBER 19, 2023

The six-page statement explains that “Brand drug manufacturers may be harming generic competition through the improper listing of patents in the. But whether a patent that only claims a device constituent of a combination product, however, was not addressed.

Drugs 105

Drugs Branding Drug Delivery Systems Generic Drugs 105

Delveinsight

NOVEMBER 29, 2020

Recent years started witnessing the emergence of novel treatment approaches that have been keeping the Retinal vein occlusion market in a hyped-up state. Looking at the potential of the pipeline therapies they hold once approved, pharmaceutical companies are charting out a seemingly exciting course in the market.

Marketing 52

Marketing Pharma Companies Drug Delivery Clinical Trials 52

XTalks

AUGUST 30, 2022

CNS drugs take more than a year longer to develop and are less than half as likely to receive marketing approval compared to other drugs, according to a 2014 study by the Tufts Center for the Study of Drug Development. There are well-established techniques for both acute and chronic drug delivery to the CSF.

Trials 83

Trials Drug Delivery Drugs Gene 83